Posters

      Development of two different methods to characterize the chemical composition of cigarette mainstream smoke

      J-Schaller, J-P. Schaller.; Plata, N.; Hofer, I.; Roudier, S.
      Conference date
      Oct 24, 2005
      Conference name
      Frontiers in Aerosol Dosimetry Research
      Link to more information
      Link to more information
      Topic
      Summary

      In order to characterize the main stream smoke while preserving its chemical compositions, two different approaches were developed. The first method is based on the trapping of the whole smoke at -183°C followed by the quantification of several smoke components using selected analytical techniques. The trapping is performed with a cryogenic instrument enabling a precise control of the temperature down to values as low as -190°C. After the trapping, the condensed smoke is diluted with a solvent and selected smoke components can be quantified using gas chromatography-mass spectrometry and liquid chromatography. The results obtained when trapping the main stream smoke of the 2R4F reference cigarette at -183°C were compared with those obtained by the standard methods. A good agreement was observed between the two approaches for 17 analytes, including some aldehydes, olefins, aromatic compounds and poly-aromatic compounds. The second method was designed to analyze the chemical composition of a single puff using gas chromatography-mass spectrometry. The smoke is sampled with a gas syringe, while the puff is being drawn. In order to evaluate the maximum number of puffs during one smoking run, an ultra-fast gas chromatograph-time of flight-mass spectrometer was used to analyze the smoke composition. The ultra-fast module enabled to analyze VOCs from isoprene to diterpenes in 1 minute. The evolution of the puff composition in the course of a smoking run was studied for the 2R4F reference cigarette, on components of both the gas and the particulate phases. 

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.